App-Quantinova.ai

Rheumatoid arthritis interstitial lung disease in ERAS and ERAN: relation to methotrexate treatment and predictive factors

Patrick D W Kiely - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

Methotrexate

In early rheumatoid arthritis, trajectory of DAS28 progression is associated with poor patient reported outcomes: results from the SERA study

James Dale - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Are the elderly with rheumatoid arthritis treated less aggressively? Findings from an inception cohort

Simone Howard - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Developing a rheumatology app to aid self-management for Torbay rheumatology patients

Kirsten Mackay - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Methotrexate

The barriers and facilitators to requesting and receiving psychological support for people with rheumatoid arthritis and adults with juvenile idiopathic arthritis

Hayley McBain - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Pro-inflammatory diets are associated with increased C-reactive protein and subsequent rheumatoid arthritis in the European Investigation of Cancer: Norfolk Arthritis Register cohort

Ellie Sayers - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Rheumatoid arthritis

N/A

Does knee pain or radiographic osteoarthritis better predict future muscle outcomes? Findings from the Hertfordshire Cohort Study

Nicholas R Fuggle - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

What is the role of UK physiotherapists in the management of people with polymyalgia rheumatica? Findings from a qualitative study

Anne V OBrien - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Changing trends and prescribing patterns in opioid treated primary care patients with non-cancer pain over a 10-year period

Meghna Jani - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

dihydrocodeine

Trends in gabapentinoid prescribing in osteoarthritis in the United Kingdom: cohort study in primary care

Thomas W Appleyard - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Gabapentin

The association of biologic drug-levels with infection risk: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

Meghna Jani - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

The impact of axial spondyloarthritis on work productivity in individuals living in rural areas: results from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS)

Rosemary J Hollick - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

High sequential use of tumour necrosis factor inhibitors in a cohort of children and young people with juvenile idiopathic arthritis from the United Kingdom

Lianne Kearsley-Fleet - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Etanercept

Frequency and reasons for switching back to etanercept originator following initial switch to etanercept biosimilar

Rebecca Davies - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Etanercept biosimilar

Using big data in the design and validation of a simulation of the healthcare system for patients with inflammatory rheumatic disease: results from the SiMSK study

Alan R Roach - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Early inflammatory arthritis

N/A

The impact of early referral and lowering clinical thresholds of biologic access on the disease course and costs in RA: results from the SiMSK study

Alan R Roach - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Among older adults aged >50 years, musculoskeletal disorders are importantly associated with health-related exit from paid work, particularly among women: findings from the HEAF study

Karen Walker-Bone - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial

John H Stone - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Tocilizumab

Long-term effect of allopurinol use on serum uric acid levels, mortality and comorbidities in gout patients: an electronic health record cohort study

Trishna Rathod-Mistry - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Gout

Allopurinol

Validation of novel juvenile idiopathic arthritis specific patient-reported outcome and experience measures

Laura E Lunt - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Rheumatoid arthritis

N/A

Filters

45280 Abstracts